Effectiveness and molecular interactions of the clinically active mTORC1 inhibitor everolimus in combination with tamoxifen or letrozole in vitro and in vivo

被引:0
作者
Lesley-Ann Martin
Sunil Pancholi
Ian Farmer
Stephanie Guest
Ricardo Ribas
Marion T Weigel
Allan M Thornhill
Zara Ghazoui
Roger A'Hern
Dean B Evans
Heidi A Lane
Stephen R Johnston
Mitch Dowsett
机构
[1] Institute of Cancer Research,Breakthrough Breast Cancer Research Centre
[2] Institute of Cancer Research,McElwain Laboratory
[3] Institute of Cancer Research,Clinical Trial Unit
[4] Novartis Institutes for BioMedical Research,undefined
[5] The Royal Marsden Hospital,undefined
来源
Breast Cancer Research | / 14卷
关键词
Breast Cancer; Estrogen Receptor; Tamoxifen; Everolimus; Letrozole;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 388 条
[31]  
Garcia-Echeverria C(2003)Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation J Biol Chem 278 30458-2467
[32]  
Shyr Y(2007)The farnesyltransferase inhibitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression in vitro and in vivo Mol Cancer Ther 6 2458-1508
[33]  
Arteaga CL(2006)mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt Cancer Res 66 1500-1160
[34]  
Pancholi S(2002)PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest Nat Med 8 1153-6369
[35]  
Lykkesfeldt AE(2009)S6 kinase 1 regulates estrogen receptor alpha in control of breast cancer cell proliferation J Biol Chem 284 6361-233
[36]  
Hilmi C(2008)Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance Endocr Rev 29 217-562
[37]  
Banerjee S(2009)Targeting PI3K signalling in cancer: opportunities, challenges and limitations Nat Rev Cancer 9 550-258
[38]  
Leary A(2001)mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer Endocr Relat Cancer 8 249-2746
[39]  
Drury S(2004)AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression J Biol Chem 279 2737-5328
[40]  
Johnston S(2005)Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer Clin Cancer Res 11 5319-44